JP2022543242A5 - - Google Patents
Info
- Publication number
- JP2022543242A5 JP2022543242A5 JP2022506657A JP2022506657A JP2022543242A5 JP 2022543242 A5 JP2022543242 A5 JP 2022543242A5 JP 2022506657 A JP2022506657 A JP 2022506657A JP 2022506657 A JP2022506657 A JP 2022506657A JP 2022543242 A5 JP2022543242 A5 JP 2022543242A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- aminosterol
- optionally substituted
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882358P | 2019-08-02 | 2019-08-02 | |
| US62/882,358 | 2019-08-02 | ||
| US202063041031P | 2020-06-18 | 2020-06-18 | |
| US63/041,031 | 2020-06-18 | ||
| PCT/US2020/044390 WO2021025973A1 (en) | 2019-08-02 | 2020-07-31 | Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543242A JP2022543242A (ja) | 2022-10-11 |
| JP2022543242A5 true JP2022543242A5 (https=) | 2025-03-21 |
| JP7819094B2 JP7819094B2 (ja) | 2026-02-24 |
Family
ID=74502413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506657A Active JP7819094B2 (ja) | 2019-08-02 | 2020-07-31 | ヒトアミノステロールｅｎｔ－０３化合物、それを含む関連組成物、およびそれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12503485B2 (https=) |
| EP (1) | EP4007764B1 (https=) |
| JP (1) | JP7819094B2 (https=) |
| CN (1) | CN114929724B (https=) |
| CA (1) | CA3149479A1 (https=) |
| MX (1) | MX2022001449A (https=) |
| WO (1) | WO2021025973A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020028810A1 (en) * | 2018-08-03 | 2020-02-06 | Enterin Laboratories | Compositions and methods for treating brain-gut disorders |
| WO2021025974A1 (en) * | 2019-08-02 | 2021-02-11 | Enterin, Inc. | Human squalamine derivatives, related compositions comprising the same, and methods of using the same |
| US20230125585A1 (en) * | 2019-08-02 | 2023-04-27 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
| WO2021216399A1 (en) * | 2020-04-20 | 2021-10-28 | Enterin, Inc. | Pulmonary aminosterol compositions and methods of using the same to treat microbial infections |
| WO2023146842A1 (en) * | 2022-01-25 | 2023-08-03 | Enterin, Inc. | C25 r and s isomers of aminosterols and methods of making and using the same |
| CN119768413A (zh) * | 2022-06-29 | 2025-04-04 | 因特尔公司 | 氨基甾醇化合物、氨基甾醇-环糊精制剂和使用它们的方法 |
| CN118085053A (zh) * | 2022-11-25 | 2024-05-28 | 深圳先进技术研究院 | 以Inx5基因或以Inx5蛋白作为作用靶点的物质的应用 |
| US12570686B1 (en) | 2024-11-15 | 2026-03-10 | BAZ Therapeutics, Inc. | Chemical structures that control metabolic elimination of aminosterols |
| CN119770654A (zh) * | 2025-01-08 | 2025-04-08 | 南京大学 | Parp1抑制剂在制备治疗和/或缓解弗里德赖希氏共济失调的药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| WO1994020520A1 (en) | 1993-03-10 | 1994-09-15 | Magainin Pharmaceuticals Inc. | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
| US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| AU3512595A (en) | 1994-09-13 | 1996-03-29 | Magainin Pharmaceuticals, Inc. | Method for inhibiting sexually transmitted diseases using magaining antimicrobials or squalamine compounds |
| US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| AU723663C (en) | 1995-06-07 | 2001-11-01 | Magainin Pharmaceuticals, Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the NHE-inhibitory efficacy of compounds |
| WO2009032321A2 (en) * | 2007-09-06 | 2009-03-12 | Genaera Corporation | A method for treating diabetes |
| MX367255B (es) | 2012-04-20 | 2019-08-12 | Ohr Pharmaceutical Inc | Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b). |
| EP2934543B1 (en) | 2012-12-20 | 2018-10-31 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
| GB201303589D0 (en) | 2013-02-27 | 2013-04-10 | Univ Swansea | Compound and method for the treatment of neurodegenerative conditions |
| GB201316050D0 (en) * | 2013-09-10 | 2013-10-23 | Univ Swansea | Deuterated compounds |
| EP3083656A1 (en) * | 2013-12-20 | 2016-10-26 | Prevacus Inc. | Synthesis of ent-progesterone and intermediates thereof |
| FR3055802B1 (fr) | 2016-09-15 | 2018-08-24 | Virbac | Derives amides de squalamine pour le traitement des infections |
| FR3055801B1 (fr) * | 2016-09-15 | 2020-10-30 | Virbac | Derives esters de squalamine pour le traitement des infections |
| US20230125585A1 (en) | 2019-08-02 | 2023-04-27 | Enterin, Inc. | Dosing protocols and regimens for aminosterol treatment |
| WO2021025974A1 (en) | 2019-08-02 | 2021-02-11 | Enterin, Inc. | Human squalamine derivatives, related compositions comprising the same, and methods of using the same |
-
2020
- 2020-07-31 US US17/631,882 patent/US12503485B2/en active Active
- 2020-07-31 CA CA3149479A patent/CA3149479A1/en active Pending
- 2020-07-31 CN CN202080068162.2A patent/CN114929724B/zh active Active
- 2020-07-31 JP JP2022506657A patent/JP7819094B2/ja active Active
- 2020-07-31 EP EP20849084.7A patent/EP4007764B1/en active Active
- 2020-07-31 WO PCT/US2020/044390 patent/WO2021025973A1/en not_active Ceased
- 2020-07-31 MX MX2022001449A patent/MX2022001449A/es unknown
-
2025
- 2025-12-10 US US19/415,736 patent/US20260098052A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022543242A5 (https=) | ||
| JP2022543244A5 (https=) | ||
| KR101166000B1 (ko) | 운동성 질환에 걸린 환자의 치료 방법 | |
| RU2302420C9 (ru) | Ингибиторы ксантин-фосфодиэстеразы v, способ их получения, фармацевтическая композиция, применение и способ лечения | |
| US20200179336A1 (en) | Methods of treating neurological and psychiatric disorders | |
| CA2517893C (fr) | Application a titre de medicaments de derives de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation | |
| EP3369730A1 (en) | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto | |
| KR101793777B1 (ko) | 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 피라졸 유도체의 용도 | |
| KR20030019455A (ko) | 수면 장애를 위한 가바펜틴 유사체 | |
| JP4896334B2 (ja) | 睡眠時呼吸障害を治療及び診断する方法並びにその方法を実施する手段 | |
| JP2016196493A (ja) | 脳虚血疾患を予防及び治療する薬剤の製造におけるｌ−ブチルフタリドの使用 | |
| JP2026031941A (ja) | 併用療法の方法、組成物およびキット | |
| CN104013638B (zh) | 当药黄素及其衍生物的用途 | |
| US20080242682A1 (en) | Preventive or Therapeutic Agent for Sleep Disorder | |
| KR102254542B1 (ko) | 과다운동성 운동 장애의 예방 및/또는 치료에 사용하기 위한 치료제 | |
| JPWO2006006617A1 (ja) | 中枢神経疾患発症後の機能障害の回復促進剤 | |
| CA2153083A1 (en) | Pharmaceutical compositions and a process for the preparation thereof | |
| JPS5955829A (ja) | 脳内の器質性障害に起因する精神機能症状の改善・治療剤 | |
| JP5198852B2 (ja) | 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物 | |
| JP2008184396A (ja) | 神経損傷に起因する身体機能障害の予防及び治療のための医薬 | |
| JPH08512305A (ja) | 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用 | |
| WO2025096683A1 (en) | Err modulators | |
| CN1105560C (zh) | 依法克生用于制备治疗亨廷顿舞蹈病的药物的应用 | |
| JP4986505B2 (ja) | 糖尿病性血管障害および呼吸障害予防および／または治療剤 | |
| TW538023B (en) | Fluorinated n-arylmethylamino derivatives of cyclobutene-3,4-diones |